title: [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study].
abstract: A total of 78 patients with superficial bladder carcinoma were prospectively randomized to two groups following complete transurethral resection (TUR). Each received 12 intravesical instillations of 10(7) units interferon A or 120 mg BCG Connaught for 1 year starting 6 weeks post-TUR. After a mean observation period of 24 (13-31) months in the BCG and 25 (6-32) months in the IFN group 5/32 (15.6%) recurrences in the BCG versus 21/35 (60%) in the IFN group were observed (P = 0.0003). In the IFN group 18.4% of the patients had dysuria and 2.6% fever; in the BCG group 35% had fever, 60% cystitis, 1 patient granulomatous epididimoorchitis and 1 patient pneumonitis with granulomatous prostatitis. With our instillation regimen interferon A had few side effects but also no prophylactic effect, whereas BCG had tolerable-seldom severe--side effects and was very effective in preventing recurrences. Perhaps IFN should be given earlier after TUR and in a higher dosage.
authors.affiliation: Urologische Abteilung, Chirurgischen Universitäts-Klinik Heidelberg.
authors.forename: T
authors.initials: T
authors.lastname: Kälble
authors.forename: M
authors.initials: M
authors.lastname: Beer
authors.forename: E
authors.initials: E
authors.lastname: Mendoza
authors.forename: U
authors.initials: U
authors.lastname: Ikinger
authors.forename: M
authors.initials: M
authors.lastname: Link
authors.forename: H E
authors.initials: HE
authors.lastname: Reichert
authors.forename: T
authors.initials: T
authors.lastname: Frangenheim
authors.forename: E
authors.initials: E
authors.lastname: Klein
authors.forename: P G
authors.initials: PG
authors.lastname: Fabricius
mesh_terms: D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004564:Electrocoagulation; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011446:Prospective Studies; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D001500:BCG Vaccine; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
vernacular_title: BCG vs. Interferon A zur Rezidivprophylaxe beim oberflächlichen Harnblasenkarzinom. Eine prospektiv randomisierte Studie.